Literature DB >> 10329551

Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.

T M Pertmer1, H L Robinson.   

Abstract

Neonatal mice have immature immune systems with defects in several components of inflammatory, innate, and specific immune responses and develop a preferential T helper type 2 response following immunization with many vaccine antigens. These studies were undertaken to determine whether 1-day-old neonatal mice immunized with plasmid DNA expressing influenza A/PR/8/34 hemagglutinin (H1) by either intramuscular (im) or gene gun (gg) inoculation were capable of generating humoral responses comparable to those in mice immunized as adults. The newborn mice developed stable, long-lived, protective anti-H1-specific IgG responses similar in titer to those of adult DNA-immunized mice. However, unlike the adult im and gg DNA immunizations, which develop polarized IgG2a and IgG1 responses, respectively, mice immunized as neonates developed a variety of IgG1, IgG2a, and mixed IgG1/IgG2a responses regardless of the inoculation method. Boosting increased but did not change these antibody profiles. In contrast to the DNA immunizations, inoculations of newborn mice with an A/PR/8/34 viral protein subunit preparation failed to elicit an antibody response. Temporal studies revealed that both responsiveness to protein vaccination and development of polarized patterns of T help following DNA immunization appeared by 2 weeks of age. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329551     DOI: 10.1006/viro.1999.9666

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

3.  DNA vaccines for influenza virus: differential effects of maternal antibody on immune responses to hemagglutinin and nucleoprotein.

Authors:  T M Pertmer; A E Oran; J M Moser; C A Madorin; H L Robinson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

5.  Neonates mount robust and protective adult-like CD8(+)-T-cell responses to DNA vaccines.

Authors:  Jie Zhang; Nicole Silvestri; J Lindsay Whitton; Daniel E Hassett
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  DNA vaccines encoding viral glycoproteins induce nonspecific immunity and Mx protein synthesis in fish.

Authors:  C H Kim; M C Johnson; J D Drennan; B E Simon; E Thomann; J A Leong
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

Review 9.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

10.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.